| 1 | 1 | | 1 of 1 |
|---|
| 2 | 2 | | HOUSE DOCKET, NO. 4409 FILED ON: 6/20/2023 |
|---|
| 3 | 3 | | HOUSE . . . . . . . . . . . . . . . No. 4068 |
|---|
| 4 | 4 | | The Commonwealth of Massachusetts |
|---|
| 5 | 5 | | _________________ |
|---|
| 6 | 6 | | PRESENTED BY: |
|---|
| 7 | 7 | | F. Jay Barrows, (BY REQUEST) |
|---|
| 8 | 8 | | _________________ |
|---|
| 9 | 9 | | To the Honorable Senate and House of Representatives of the Commonwealth of Massachusetts in General |
|---|
| 10 | 10 | | Court assembled: |
|---|
| 11 | 11 | | The undersigned legislators and/or citizens respectfully petition for the adoption of the accompanying bill: |
|---|
| 12 | 12 | | An Act relative to diabetic financial protection, assistance, and additional healthcare coverage. |
|---|
| 13 | 13 | | _______________ |
|---|
| 14 | 14 | | PETITION OF: |
|---|
| 15 | 15 | | NAME:DISTRICT/ADDRESS :DATE ADDED:Julie Mejia274 East Main Street, Suite 3305, |
|---|
| 16 | 16 | | Norton, MA 02766 |
|---|
| 17 | 17 | | 6/20/2023 1 of 2 |
|---|
| 18 | 18 | | HOUSE DOCKET, NO. 4409 FILED ON: 6/20/2023 |
|---|
| 19 | 19 | | HOUSE . . . . . . . . . . . . . . . No. 4068 |
|---|
| 20 | 20 | | By Representative Barrows of Mansfield (by request), a petition (subject to Joint Rule 12) of |
|---|
| 21 | 21 | | Julie Mejia relative to health insurance coverage for diabetic products. Financial Services. |
|---|
| 22 | 22 | | The Commonwealth of Massachusetts |
|---|
| 23 | 23 | | _______________ |
|---|
| 24 | 24 | | In the One Hundred and Ninety-Third General Court |
|---|
| 25 | 25 | | (2023-2024) |
|---|
| 26 | 26 | | _______________ |
|---|
| 27 | 27 | | An Act relative to diabetic financial protection, assistance, and additional healthcare coverage. |
|---|
| 28 | 28 | | Be it enacted by the Senate and House of Representatives in General Court assembled, and by the authority |
|---|
| 29 | 29 | | of the same, as follows: |
|---|
| 30 | 30 | | 1 SECTION 1. Chapter 175 of the General Laws, as appearing in the 2020 Official Edition, |
|---|
| 31 | 31 | | 2is hereby amended by inserting the following section:- |
|---|
| 32 | 32 | | 3 Section 47UU. (a) For the purposes of this section, the following terms shall have the |
|---|
| 33 | 33 | | 4following meanings unless the context clearly requires otherwise: |
|---|
| 34 | 34 | | 5 “Diabetic products”, prescription medications, diabetic testing supplies, and medical |
|---|
| 35 | 35 | | 6equipment necessary for treating diabetes. |
|---|
| 36 | 36 | | 7 “Smart InPens”, are all reusable insulin pens for the treatment of both Type 1 and Type 2 |
|---|
| 37 | 37 | | 8diabetes, which may include additional features, such as Bluetooth technology. |
|---|
| 38 | 38 | | 9 (b) Health insurance providers shall ensure that diabetic products adhere to the following |
|---|
| 39 | 39 | | 10price standards: (1) The general price of diabetic testing strips shall not exceed $10 per monthly |
|---|
| 40 | 40 | | 11supply of test strips. (2) The general price of diabetic lancets shall not exceed $10 per monthly |
|---|
| 41 | 41 | | 12supply of lancets. (3) The general price of diabetic pen needles and syringes shall not exceed $10 2 of 2 |
|---|
| 42 | 42 | | 13per monthly supply of pen needles and syringes. (4) The general price of insulin pumps and |
|---|
| 43 | 43 | | 14delivery systems shall not exceed $100 per pump. (5) The general price of a monthly supply of |
|---|
| 44 | 44 | | 15infusion sets for delivery systems shall not exceed $10 per month. (6) The general price of |
|---|
| 45 | 45 | | 16insulin cartridges for delivery devices shall not exceed $10 per month. (7) The general price of |
|---|
| 46 | 46 | | 17CGM transmitters shall not exceed $20 per transmitter. (8) The general price of a monthly supply |
|---|
| 47 | 47 | | 18of CGM sensors shall not exceed $20 per monthly supply. (9) The general price of insulin pens |
|---|
| 48 | 48 | | 19or vials shall not exceed $15 per month for vials or pens necessary for the treatment of patients. |
|---|
| 49 | 49 | | 20(10) The general price of blood glucose meters and monitoring systems shall not exceed $20 per |
|---|
| 50 | 50 | | 21system. (11) The general price of oral diabetes medication shall not exceed $10 per monthly |
|---|
| 51 | 51 | | 22supply of medication. (12) The general price of diabetic stem cell therapies shall not exceed $100 |
|---|
| 52 | 52 | | 23per session. (13) The general price of Smart InPens shall not exceed $20 per InPen. (14) If a |
|---|
| 53 | 53 | | 24patient requires three or more discrete diabetic medications, testing supplies, or equipment, the |
|---|
| 54 | 54 | | 25patient shall not be required to pay more than $100 a month for costs related to diabetes |
|---|
| 55 | 55 | | 26treatment. |
|---|
| 56 | 56 | | 27 (c) Nothing in this section shall be construed to limit the requirements for MassHealth to |
|---|
| 57 | 57 | | 28provide additional coverage for diabetic medication and healthcare-related products. |
|---|
| 58 | 58 | | 29 SECTION 2. Section 1 of this act shall take effect on January 1, 2024. |
|---|